ResoTher Pharma A/S

CVR 37852406 · Public limited company (A/S) · Active · High risk

ResoTher Pharma A/S is a Public limited company (A/S), founded on , based in Holte. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 4.5% over the next 12 months, which is 3.2 times the average for Danish companies. 9 annual reports have been published, of which 2 more than six months after the end of the financial year.

Bankruptcy risk for ResoTher Pharma A/S

4.5%
probability of bankruptcy within 12 months
High risk

3.2 × the average (1.41%) · higher risk than 91% of active Danish companies

Lowest riskHighest risk

Increases the risk

Number of CEOs0 · bankruptcy rate 12.7%1.4×
CEOs in total (historical)0 · bankruptcy rate 12.4%1.4×
RegionHovedstaden · bankruptcy rate 11.6%1.3×
CEO's other companies0 · bankruptcy rate 10.9%1.2×
Annual reports filed late2 · bankruptcy rate 10.4%1.2×
Employees (latest year)2–5 · bankruptcy rate 10.3%1.2×
Other companies at the same address20–100 · bankruptcy rate 10.2%1.2×

Reduces the risk

Time at current address5+ yrs · bankruptcy rate 3.1%0.35×
Reporting classReporting class B · bankruptcy rate 3.2%0.37×
Age (years)10–20 yrs · bankruptcy rate 3.9%0.45×
Company typeA/S · bankruptcy rate 4.4%0.50×
Share of late annual reports0.01%–25% · bankruptcy rate 4.5%0.51×
Number of auditors (historical)2 · bankruptcy rate 4.6%0.52×
Auditor registered in CVRYes · bankruptcy rate 4.8%0.55×
Audit opted outNo · bankruptcy rate 4.8%0.55×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
37852406
Status
Active
Company type
Public limited company (A/S)
Founded
(10 years)
Address
c/o "Næsseslottet", Dronninggårds Alle 136
2840 Holte
Municipality
Rudersdal
Industry
Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Share capital
DKK 609k
Employees
2 (2018)
Auditor
EY Godkendt Revisionspartnerselskab
Audit opted out
No

Warning signs

Annual reports filed late2 of 9
Missing annual reportNo
Negative equity–
Equity ratio–
Current ratio–
Moves (last 2 years)0
CEO changes in total0
CEO's previous bankruptcies0
Other companies at the address32
Going-concern uncertaintyNo

Financials and key figures

Financial year2025
Avg. employees3

Latest annual report: Reporting class B · auditor's statement: Auditor's report on audited financial statements · EY Godkendt Revisionspartnerselskab.

Filed annual reports

Reporting periodPublishedDays after period end
1 Jan 2025 – 31 Dec 2025188 Late
1 Jan 2024 – 31 Dec 2024180
1 Jan 2023 – 31 Dec 2023180
1 Jan 2022 – 31 Dec 2022186 Late
1 Jan 2021 – 31 Dec 2021175
1 Jan 2020 – 31 Dec 2020167
1 Jan 2019 – 31 Dec 2019177
1 Jan 2018 – 31 Dec 2018156
4 Jul 2016 – 31 Dec 2017163

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
BoardHenrik StageCurrent
BoardJeppe Øvli ØvlesenCurrent
BoardSven Martin JacobsonCurrent
BoardRoderick John FlowerCurrent
BoardThomas Engelbrecht Nordkild JonassenCurrent
BoardRebecca Anne MorisonCurrent
BoardMichael Østerlund MadsenCurrent
BoardJeppe Øvli Øvlesen
BoardThomas Engelbrecht Nordkild Jonassen
BoardLone Merete Veng
BoardMette Munch
BoardKirsten Aarup Drejer
BoardKirsten Aarup Drejer
BoardLars Henning Stigel
BoardThomas Feldthus
BoardThomas Engelbrecht Nordkild Jonassen
BoardRebecca Anne Morison
Owner (5%)Quantass ApSCurrent
Owner (5%)TJ Biotech Holding ApSCurrent
Owner (50%)TJ BIOTECH HOLDING ApS
Owner (50%)QUANTASS ApS
Owner (15%)Lone Merete Veng
Owner (33%)TJ BIOTECH HOLDING ApS
Owner (33%)QUANTASS ApS
Owner (15%)Pinnacle Holding ApS
Owner (5%)Mauro Antonia Italo Perretti
Owner (25%)TJ BIOTECH HOLDING ApS
Owner (15%)Uddannelses- og Forskningsstyrelsen
Owner (25%)QUANTASS ApS
Owner (10%)Pinnacle Holding ApS
Owner (20%)TJ BIOTECH HOLDING ApS
Owner (10%)Uddannelses- og Forskningsstyrelsen
Owner (20%)QUANTASS ApS
Owner (5%)Pinnacle Holding ApS
Owner (15%)TJ BIOTECH HOLDING ApS
Owner (15%)QUANTASS ApS
Owner (15%)Quantass ApS
Owner (15%)TJ Biotech Holding ApS
Owner (5%)Uddannelses- og Forskningsstyrelsen
Owner (10%)Quantass ApS
Owner (10%)TJ Biotech Holding ApS
AuditorEY Godkendt RevisionspartnerselskabCurrent
AuditorPRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB
FounderTJ BIOTECH HOLDING ApSCurrent
FounderQUANTASS ApSCurrent

Address history (0 moves)

c/o "Næsseslottet", Dronninggårds Alle 136, 2840 Holte

Former names

ResoTher Pharma A/S – now
ResoTher Pharma ApS –

Employees per year

Number of employees at ResoTher Pharma A/S per year122017: 120172018: 22018

Other companies at the same address

Similar companies in Rudersdal

Questions and answers about ResoTher Pharma A/S

Has ResoTher Pharma A/S gone bankrupt?

No, ResoTher Pharma A/S is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of ResoTher Pharma A/S?

Our model estimates a bankruptcy risk of 4.5% over the next 12 months (high risk), which is 3.2 times the average for Danish companies.

Who is the auditor of ResoTher Pharma A/S?

ResoTher Pharma A/S most recently used EY Godkendt Revisionspartnerselskab.

When was ResoTher Pharma A/S founded?

ResoTher Pharma A/S was founded on 4 July 2016.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.